Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12613000107729
ACTRN12613000107729
Active, not recruiting
Phase 4

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer:A prospective controlled Trial from China

Changhai Hospital, Second Military Medical University0 sites100 target enrollmentJanuary 29, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsprostate cancerCancer - Prostate

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
prostate cancer
Sponsor
Changhai Hospital, Second Military Medical University
Enrollment
100
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 29, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Changhai Hospital, Second Military Medical University

Eligibility Criteria

Inclusion Criteria

  • •.Inclusion Criteria (run\-in period):
  • •1\)Histologically confirmed adenocarcinoma of the prostate
  • •2\)T1\-T4, metastatic (M1\) prostate cancer, T1\-T4, non\-metastatic (M0\), N\+ prostate cancer
  • •.Inclusion criteria to the randomised period:
  • •All patients recruited received the LHRHa goserelin acetate(Zoladex 3\.6mg) subcutaneously every 28 days and bicalutamide(Casodex 50mg) orally once daily for 8 months(run in) before randomization. Patients in whom PSA decreased to less than 4\.0ng/ml were randomized to IAD or CAD.

Exclusion Criteria

  • •.Exclusion Criteria (run\-in period):
  • •Any previous or concurrent treatment of prostate cancer, except TURP, 5\-alpha reductase inhibitor, radical prostatectomy or radiotherapy Any medication/treatment affecting sex hormone status
  • •.Exclusion Criteria:
  • •Patients in whom prostate specific antigen decreased to no less than 4ng/ml were excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
atural Course of Hot Flash Symptoms in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer – a Pilot Investigation.atural course of hot flashes in men with prostate cancer, receiving ADT for the first time.Natural course of hot flashes in men with prostate cancer, receiving ADT for the first time.Cancer - Prostate
ACTRN12613000566730A/Professor Henry Woo20
Active, not recruiting
Not Applicable
Testing the addition of new treatments to standard treatment in prostate cancer that has spread to other areas of the bodyMetastatic hormone-sensitive prostate cancerCancer
ISRCTN66357938niversity College London4,914
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMetastatic prostate cancerMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004853-26-FITurku University Hospital35
Active, not recruiting
Phase 1
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)
EUCTR2017-002345-29-FITurku University Hospital5
Recruiting
Not Applicable
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.
ACTRN12617001116314St Vincent's Hospital, Sydney20